A study published in the journal Cancers shows that tumor locations present different prognostic implications in diffuse large B-cell lymphoma (DLBCL).
“The prognostic role of primary tumor location for clinical outcomes of patients with early-stage DLBCL remains uncertain,” the researchers wrote.
Researchers assessed the link between primary tumor site and overall survival (OS) in 9,738 early-stage nodal DLBCL patients from the Surveillance, Epidemiology, and End Results (SEER) database. The primary site of the tumors was characterized as supradiaphragm and subdiaphragm according to the definition of lymph node distribution in staging.
According to the results, the OS was significantly better for patients of the supradiaphragm group (n=6,038) compared to the ones from the subdiaphragm group (n= 3,655) (hazard ratio (HR) 1.24; 95%CI: 1.16-1.33; P < 0.001), and it was preserved after propensity score matching (PSM) (HR 1.15; 95% CI: 1.07-1.24; P < 0.001). The researchers noted that gene enrichment analyses showed that the subdiaphragm group has an upregulated extracellular matrix (ECM)-related signaling, which promotes disease growth, invasion, and metastasis, and downregulated interferon response, which is considered to have anti-tumor function.
“Our results indicate the two tumor locations (supradiaphragm and subdiaphragm) presented different prognostic implications for the overall survival, suggesting that the tumor’s location could serve as a prognostic biomarker for early-stage nodal DLBCL patients,” the researchers concluded.